Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets

博士 === 國立陽明大學 === 臨床醫學研究所 === 102 === Dysregulation of multiple signaling cascades, which could be regulated by protein phosphorylation and protein-protein interactions (PPIs), is often detected in cancers. Deciphering the signaling pathway networks via PPIs at the cellular level is a promising appr...

Full description

Bibliographic Details
Main Authors: Tzu-Chi Chen, 陳咨錡
Other Authors: Chi-Ying Huang
Format: Others
Language:en_US
Published: 2014
Online Access:http://ndltd.ncl.edu.tw/handle/14008443669347972453
id ndltd-TW-102YM005521020
record_format oai_dc
spelling ndltd-TW-102YM0055210202015-10-13T23:50:04Z http://ndltd.ncl.edu.tw/handle/14008443669347972453 Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets 以系統化分析蛋白質交互作用網絡開發新的癌症治療標的 Tzu-Chi Chen 陳咨錡 博士 國立陽明大學 臨床醫學研究所 102 Dysregulation of multiple signaling cascades, which could be regulated by protein phosphorylation and protein-protein interactions (PPIs), is often detected in cancers. Deciphering the signaling pathway networks via PPIs at the cellular level is a promising approach for targeting cancers but remains incomplete. The final goal of this study is to establish the PPI-pathway network in cancers for elucidating new therapeutic candidates. Here, we used an in situ proximity ligation assay (in situ PLA) to systematically identify the EGFR phosphorylation change and 624 endogenous PPIs in cancer cells. Fourteen EGFR phosphorylation sites were characterized with distinct EGF dependency upon EGFR genotypes in lung cancer cell. We demonstrated a novel interaction, EGFR-AURKA, which might mediate AURKA-elicited phosphorylation at EGFR-Thr654 and -Ser1046 in EGFR mutant lung cancer cells. Moreover, we detected 67 endogenous PPIs among 21 interlinked pathways in hepatocellular carcinoma (HCC) cells. The expression of novel interaction, CRKL-FLT1 is strongly correlated with the migratory ability of HCC. CRKL and the CRKL-FLT1 were identified as novel prognosis markers by immunohistochemical analysis of 192 HCC patients. We also uncovered the HCC patients with lower expression of FLT1 was associated with hypertension. In addition to HCC, 557 endogenous PPIs in HeLa cells were validated for pathway network. Based on Reactome annotations, 90 PPIs of them were cross-talk PPIs linking 17 signaling pathways. The top 2 connected cross-talk PPIs are MAPK3-DAPK1 and FAS-PRKCA interactions, which link 9 and 8 pathways, respectively. In summary, this study not only prove the concept that functional exploration of a disease network with PPI-pathway network can be used to discover novel biomarkers, but also establish the systematic profile of PPIs for comprehensive analysis of the human interactome. Chi-Ying Huang 黃奇英 2014 學位論文 ; thesis 269 en_US
collection NDLTD
language en_US
format Others
sources NDLTD
description 博士 === 國立陽明大學 === 臨床醫學研究所 === 102 === Dysregulation of multiple signaling cascades, which could be regulated by protein phosphorylation and protein-protein interactions (PPIs), is often detected in cancers. Deciphering the signaling pathway networks via PPIs at the cellular level is a promising approach for targeting cancers but remains incomplete. The final goal of this study is to establish the PPI-pathway network in cancers for elucidating new therapeutic candidates. Here, we used an in situ proximity ligation assay (in situ PLA) to systematically identify the EGFR phosphorylation change and 624 endogenous PPIs in cancer cells. Fourteen EGFR phosphorylation sites were characterized with distinct EGF dependency upon EGFR genotypes in lung cancer cell. We demonstrated a novel interaction, EGFR-AURKA, which might mediate AURKA-elicited phosphorylation at EGFR-Thr654 and -Ser1046 in EGFR mutant lung cancer cells. Moreover, we detected 67 endogenous PPIs among 21 interlinked pathways in hepatocellular carcinoma (HCC) cells. The expression of novel interaction, CRKL-FLT1 is strongly correlated with the migratory ability of HCC. CRKL and the CRKL-FLT1 were identified as novel prognosis markers by immunohistochemical analysis of 192 HCC patients. We also uncovered the HCC patients with lower expression of FLT1 was associated with hypertension. In addition to HCC, 557 endogenous PPIs in HeLa cells were validated for pathway network. Based on Reactome annotations, 90 PPIs of them were cross-talk PPIs linking 17 signaling pathways. The top 2 connected cross-talk PPIs are MAPK3-DAPK1 and FAS-PRKCA interactions, which link 9 and 8 pathways, respectively. In summary, this study not only prove the concept that functional exploration of a disease network with PPI-pathway network can be used to discover novel biomarkers, but also establish the systematic profile of PPIs for comprehensive analysis of the human interactome.
author2 Chi-Ying Huang
author_facet Chi-Ying Huang
Tzu-Chi Chen
陳咨錡
author Tzu-Chi Chen
陳咨錡
spellingShingle Tzu-Chi Chen
陳咨錡
Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets
author_sort Tzu-Chi Chen
title Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets
title_short Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets
title_full Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets
title_fullStr Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets
title_full_unstemmed Systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets
title_sort systematic analyses of protein-protein interaction network for identifying new cancer therapeutic targets
publishDate 2014
url http://ndltd.ncl.edu.tw/handle/14008443669347972453
work_keys_str_mv AT tzuchichen systematicanalysesofproteinproteininteractionnetworkforidentifyingnewcancertherapeutictargets
AT chénzīqí systematicanalysesofproteinproteininteractionnetworkforidentifyingnewcancertherapeutictargets
AT tzuchichen yǐxìtǒnghuàfēnxīdànbáizhìjiāohùzuòyòngwǎngluòkāifāxīndeáizhèngzhìliáobiāode
AT chénzīqí yǐxìtǒnghuàfēnxīdànbáizhìjiāohùzuòyòngwǎngluòkāifāxīndeáizhèngzhìliáobiāode
_version_ 1718087479264804864